he Supreme Court's landmark judgment on the Novartis Glivec case — disallowing a patent on minor modifications — has started a global debate. How will the ruling impact patents and patients, in India and elsewhere? It's obviously impossible to predict the future. But some informed guesses can be made. We should start with a clear idea who the main stakeholders are.